Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M.

J Immunother Cancer. 2018 Jun 4;6(1):45. doi: 10.1186/s40425-018-0354-6.

2.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M.

J Immunother Cancer. 2018 Apr 30;6(1):31. doi: 10.1186/s40425-018-0329-7. Erratum in: J Immunother Cancer. 2018 Jun 4;6(1):45.

3.

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.

Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD.

Clin Cancer Res. 2016 Nov 1;22(21):5204-5210. Epub 2016 Oct 19.

4.

Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.

Yin Y, Ren X, Smith C, Guo Q, Malabunga M, Guernah I, Zhang Y, Shen J, Sun H, Chehab N, Loizos N, Ludwig DL, Ornitz DM.

Dis Model Mech. 2016 May 1;9(5):563-71. doi: 10.1242/dmm.024760. Epub 2016 Apr 7.

5.

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor.

Forest A, Amatulli M, Ludwig DL, Damoci CB, Wang Y, Burns CA, Donoho GP, Zanella N, Fiebig HH, Prewett MC, Surguladze D, DeLigio JT, Houghton PJ, Smith MA, Novosiadly R.

Mol Cancer Res. 2015 Dec;13(12):1615-26. doi: 10.1158/1541-7786.MCR-15-0279. Epub 2015 Aug 11.

6.

A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.

Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL.

MAbs. 2015;7(5):931-45. doi: 10.1080/19420862.2015.1055442.

7.

Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.

Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY, He QY, Cheung AL.

Clin Cancer Res. 2014 May 15;20(10):2651-62. doi: 10.1158/1078-0432.CCR-13-2735. Epub 2014 Mar 5.

8.

Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes.

Kang YK, Hamzik J, Felo M, Qi B, Lee J, Ng S, Liebisch G, Shanehsaz B, Singh N, Persaud K, Ludwig DL, Balderes P.

Biotechnol Bioeng. 2013 Nov;110(11):2928-37. doi: 10.1002/bit.24969. Epub 2013 Jun 29.

9.

Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.

Shen Y, Zeng L, Zhu A, Blanc T, Patel D, Pennello A, Bari A, Ng S, Persaud K, Kang YK, Balderes P, Surguladze D, Hindi S, Zhou Q, Ludwig DL, Snavely M.

MAbs. 2013 May-Jun;5(3):418-31. doi: 10.4161/mabs.24291. Epub 2013 Apr 8.

10.

A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.

Haidar JN, Yuan QA, Zeng L, Snavely M, Luna X, Zhang H, Zhu W, Ludwig DL, Zhu Z.

Proteins. 2012 Mar;80(3):896-912. doi: 10.1002/prot.23246. Epub 2011 Dec 16. Erratum in: Proteins. 2013 Sep;81(9):1677.

PMID:
22180101
11.

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.

Rowinsky EK, Schwartz JD, Zojwalla N, Youssoufian H, Fox F, Pultar P, Novosyadlyy R, Cosaert J, Ludwig DL.

Curr Drug Targets. 2011 Dec;12(14):2016-33. Review.

PMID:
21777192
12.

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

Attias-Geva Z, Bentov I, Ludwig DL, Fishman A, Bruchim I, Werner H.

Eur J Cancer. 2011 Jul;47(11):1717-26. doi: 10.1016/j.ejca.2011.02.019. Epub 2011 Mar 28.

PMID:
21450456
13.

IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.

Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X.

Hum Antibodies. 2010;19(4):89-99. doi: 10.3233/HAB-2010-0232.

PMID:
21178280
14.

Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.

Galer CE, Corey CL, Wang Z, Younes MN, Gomez-Rivera F, Jasser SA, Ludwig DL, El-Naggar AK, Weber RS, Myers JN.

Head Neck. 2011 Feb;33(2):189-98. doi: 10.1002/hed.21419.

15.

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Ulanet DB, Ludwig DL, Kahn CR, Hanahan D.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8. doi: 10.1073/pnas.0914076107. Epub 2010 May 10.

16.

Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.

Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.

Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9.

17.

Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.

Sprenger CC, Haugk K, Sun S, Coleman I, Nelson PS, Vessella RL, Ludwig DL, Wu JD, Plymate SR.

Clin Cancer Res. 2009 Dec 15;15(24):7634-7641.

18.

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

Tonra JR, Corcoran E, Deevi DS, Steiner P, Kearney J, Li H, Ludwig DL, Zhu Z, Witte L, Surguladze D, Hicklin DJ.

Anticancer Res. 2009 Jun;29(6):1999-2007.

19.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z.

Neoplasia. 2009 Jun;11(6):594-604.

20.

Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells.

Rowzee AM, Ludwig DL, Wood TL.

Endocrinology. 2009 Aug;150(8):3611-9. doi: 10.1210/en.2008-1473. Epub 2009 Apr 30.

21.

HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia.

Whelan JT, Ludwig DL, Bertrand FE.

Leukemia. 2008 Jun;22(6):1161-9. doi: 10.1038/leu.2008.57. Epub 2008 Mar 13.

PMID:
18337761
22.

Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.

Patel D, Balderes P, Lahiji A, Melchior M, Ng S, Bassi R, Wu Y, Griffith H, Jimenez X, Ludwig DL, Hicklin DJ, Kang X.

Hum Antibodies. 2007;16(3-4):127-36.

PMID:
18334748
23.

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.

Lung Cancer. 2008 May;60(2):166-74. Epub 2007 Nov 14.

PMID:
18006183
24.

An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.

Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Wu JD.

Clin Cancer Res. 2007 Nov 1;13(21):6429-39.

25.

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. Review.

26.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL, Zhu Z.

Biochem Biophys Res Commun. 2007 Jun 15;357(4):1142-7. Epub 2007 Apr 19.

PMID:
17462601
27.

Insulin-like growth factor-I receptor signaling blockade combined with radiation.

Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM.

Cancer Res. 2007 Feb 1;67(3):1155-62.

28.

Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.

Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z.

J Immunol Methods. 2007 Jan 10;318(1-2):65-74. Epub 2006 Oct 26.

PMID:
17126853
29.

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.

Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.

Clin Cancer Res. 2006 Nov 1;12(21):6573-84.

30.

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Plymate SR.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6153-60.

31.

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS.

Cancer Res. 2006 Sep 15;66(18):9162-70.

32.
33.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Miao HQ, Hu K, Jimenez X, Navarro E, Zhang H, Lu D, Ludwig DL, Balderes P, Zhu Z.

Biochem Biophys Res Commun. 2006 Jun 23;345(1):438-45. Epub 2006 May 2.

PMID:
16682007
34.

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA.

Leukemia. 2006 Jul;20(7):1254-60. Epub 2006 Apr 27.

PMID:
16642049
35.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N.

Cancer Res. 2006 Feb 1;66(3):1500-8.

36.

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.

Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR.

Clin Cancer Res. 2005 Apr 15;11(8):3065-74.

37.

Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P.

Mol Cancer Ther. 2005 Mar;4(3):369-79.

38.

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9.

39.

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.

Piloto O, Levis M, Huso D, Li Y, Li H, Wang MN, Bassi R, Balderes P, Ludwig DL, Witte L, Zhu Z, Hicklin DJ, Small D.

Cancer Res. 2005 Feb 15;65(4):1514-22.

40.

Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.

Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D, Pereira DS, Jimenez X, Fox F, Saxena B, Zhou Q, Ma Y, Kang X, Patel D, Barry M, Kussie P, Zhu Z, Russell DA, Petersen WL, Jury TP, Gaitan-Gaitan F, Moran DL, Delannay X, Storrs BS, Tou J, Zupec ME, Gustafson KS, McIntyre J, Tarnowski SJ, Bohlen P.

Hum Antibodies. 2004;13(3):81-90. Erratum in: Hum Antibodies. 2009;18(4):157. Dosage error in article text.

PMID:
15598988
41.
42.

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Li Y, Li H, Wang MN, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ.

Blood. 2004 Aug 15;104(4):1137-44. Epub 2004 Apr 22.

43.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.

Cancer Res. 2003 Dec 15;63(24):8912-21.

44.

Monoclonal antibody therapeutics and apoptosis.

Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P.

Oncogene. 2003 Dec 8;22(56):9097-106. Review.

PMID:
14663488
45.

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.

Leukemia. 2003 Mar;17(3):604-11.

PMID:
12646950
46.

Cloning, genetic characterization, and chromosomal mapping of the mouse VDUP1 gene.

Ludwig DL, Kotanides H, Le T, Chavkin D, Bohlen P, Witte L.

Gene. 2001 May 16;269(1-2):103-12.

PMID:
11376942
47.

Cloning and functional expression of a human heparanase gene.

Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P.

Biochem Biophys Res Commun. 1999 Jul 22;261(1):183-7.

PMID:
10405343
48.

A murine AP-endonuclease gene-targeted deficiency with post-implantation embryonic progression and ionizing radiation sensitivity.

Ludwig DL, MacInnes MA, Takiguchi Y, Purtymun PE, Henrie M, Flannery M, Meneses J, Pedersen RA, Chen DJ.

Mutat Res. 1998 Oct 21;409(1):17-29.

PMID:
9806499
49.

Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element.

Ludwig DL, Chen F, Peterson SR, Nussenzweig A, Li GC, Chen DJ.

Gene. 1997 Oct 15;199(1-2):181-94.

PMID:
9358055

Supplemental Content

Loading ...
Support Center